Does Rallies show 13F holders for VRDN?

Yes. Rallies tracks hedge fund and 13F ownership data for VRDN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VRDN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VRDN. It does not provide personalized investment advice.

VRDN (Viridian Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Viridian Therapeutics, Inc. Common Stock (VRDN) is a publicly traded Healthcare sector company. As of May 21, 2026, VRDN trades at $17.55 with a market cap of $1.78B and a P/E ratio of 0.00. VRDN moved +10.36% today. Year to date, VRDN is -41.62%; over the trailing twelve months it is +27.57%. Its 52-week range spans $9.90 to $34.29. Analyst consensus is strong buy with an average price target of $32.08. Rallies surfaces VRDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VRDN stock?

Hedge funds tracked by Rallies that own VRDN include Maverick Capital, Panagora Asset, and Centerbook Partners. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Viridian Therapeutics, Inc. Common Stock.

VRDN Key Metrics

Key financial metrics for VRDN
Metric	Value
Price	$17.55
Market Cap	$1.78B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$34.29
52-Week Low	$9.90
Volume	44
Avg Volume	0
Revenue (TTM)	$70.85M
Net Income	$-342.60M
Gross Margin	0.00%

Top Hedge Funds Holding VRDN

Maverick Capital holds 2.21M shares of VRDN, changed -1.96% as of Sep 30, 2025.
Panagora Asset holds 313.70K shares of VRDN, changed -3.40% as of Mar 31, 2026.
Centerbook Partners holds 45.34K shares of VRDN, changed -66.84% as of Mar 31, 2026.

Latest VRDN News

Viridian Therapeutics Shares Surge 35.6% After REVEAL-2 Phase III TED Success — May 6, 2026
Viridian shares tumble 38% despite Phase III elegrobart achieving up to 63% response — Mar 30, 2026
Viridian’s Phase 3 TED Trial Shows 54% Proptosis and 71% Diplopia Response — Mar 30, 2026

Recent VRDN Insider Trades

Fairmount Funds Management LLC bought 1.18M (~$20.00M) on May 11, 2026.
Tousignant Jennifer sold 2.27K (~$70.80K) on Dec 31, 2025.
Fairmount Funds Management LLC bought 454.55K (~$10.00M) on Oct 23, 2025.

VRDN Analyst Consensus

14 analysts cover VRDN: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.08.

Common questions about VRDN

Who owns VRDN stock?: Hedge funds tracked by Rallies that own VRDN include Maverick Capital, Panagora Asset, and Centerbook Partners. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Viridian Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for VRDN?: Yes. Rallies tracks hedge fund and 13F ownership data for VRDN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VRDN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VRDN. It does not provide personalized investment advice.